Latest Industry Insights
Industry Insight
Early Detection of Autoantibodies in Type 1 Diabetes Mellitus and Treatment Possibilities Beyond Insulin
In this article, we discuss the use of autoantibodies to diagnose and monitor type 1 diabetes mellitus and provide some future perspectives on potential therapies beyond insulin.
Industry Insight
MDMA for Traumatic Brain Injury To Be Studied in $1.5 Million Partnership
A new partnership between MAPS Public Benefit Corp (PBC) and Wesana Health will see $1.5 million contributed towards investigation into the therapeutic potential of the psychedelic compound MDMA in treating traumatic brain injury (TBI).
Industry Insight
Simulator Technology Can Predict Optimal Vaccine Dosing
Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.
Industry Insight
Making Bioassay Data Easier To Retrieve and Share
Technology Networks had the pleasure of speaking with Dr. Vladimir Makarov, project manager of the Pistoia Alliance Artificial Intelligence and Machine Learning Centre of Excellence, to learn more about the DataFAIRy project, its aims and importance.
Industry Insight
The Five Steps Needed To Turn AI Hype in Life Science Into Reality
How can R&D leaders turn the huge potential of AI into real-world success? In this article, James Malone, CTO, SciBite (an Elsevier company), looks at five ways to unlock the value of AI.
Industry Insight
Patient Simulators: From CPR Dummies to Mixed Reality High-Fidelity Robots
Technology Networks spoke to James Archetto, vice president at Gaumard Scientific, to learn more about the history of patient simulators, most recent advances and what is on the horizon.
Industry Insight
How Can AI Techniques Improve How We Diagnose Dementia?
Developing treatments for dementia remains one of the most forbidding challenges facing neurology. Traditionally, paper-based assessments are used by clinicians to diagnose patients. But London-based company Cognetivity says that its AI-based platform could improve diagnostics. We spoke with the company’s co-founder and chief science officer, Dr. Seyed Khaligh-Razavi, to find out more.
Industry Insight
Humanized Mice: Generation, Advantages and Applications
Technology Networks recently spoke with Dr. Marvin Ouyang, Cyagen’s executive vice president and chief scientific officer, to learn more about humanized mice and the applications they can benefit. In this interview Dr. Ouyang also explains how humanized mice can be generated and highlights some of Cyagen’s capabilities in this area.
Industry Insight
How Can We Make It Easier To Implant a Brain-Computer Interface?
Brain-computer interfaces (BCI) have the potential to revolutionize the lives of people with severe motor and nervous system impairments. But users of current BCI technology must face the hurdle of implanting the device in their brain. We spoke to Professor Florian Solzbacher, co-founder and chairman of Blackrock, to find out more about how neurotechnology companies are overcoming this obstacle.
Industry Insight
How LC-MS Can Support SARS-CoV-2 Research
In this interview, Kevin Wyndham, senior director of research and development at Waters, highlights how a new LC-MS method could be used to support research both during and beyond the COVID-19 pandemic.
Advertisement